Literature DB >> 25190017

Meta-analysis of studies on the association between the NF-κB1-94ins/del ATTG promoter polymorphism and cancer.

Xuewu Nian1, Wei Zhang, Limin Li, Yan Sun, Erlin Sun, Ruifa Han.   

Abstract

Nuclear factor-kappa B (NF-κB), a cell survival signal, is involved in carcinogenesis. Polymorphism of NF-κB1 is associated with cancer by several studies. This study aims to perform a comprehensive meta-analysis of studies and determine the association between the NF-κB1-94ins/del ATTG promoter polymorphism and cancer. Twenty-five case-control studies (7,281 cases and 10,039 controls) were included. We used odds ratios (ORs) to assess the strength of the association, and 95 % confidence intervals (CIs) to identify precision of the estimate. Overall, NF-κB1-94ins/del ATTG promoter polymorphism was significantly associated with decreased susceptibility to cancer in overall population under homozygote (for DD vs. WW: OR = 0.74, 95 % CI = 0.58-0.96), recessive (for DD vs. WD+WW: OR = 0.82, 95 % CI = 0.69-0.99), dominant (for DD+WD vs. WW: OR = 0.84, 95 % CI = 0.71-1.00), and allele (for D vs. W: OR = 0.88, 95 % CI = 0.78-0.98) model. Subgroup analysis for ethnicity found that NF-κB1-94ins/del ATTG promoter polymorphism was significantly associated with decreased susceptibility to cancer in Asians (for DD vs. WW: OR = 0.54, 95 % CI = 0.40-0.74; for WD vs. WW: OR = 0.75, 95 % CI = 0.69-0.81; for DD vs. WD+WW: OR = 0.70, 95 % CI = 0.55-0.90; for DD+WD vs. WW; OR = 0.66, 95 % CI = 0.56-0.78; for D vs. W: OR = 0.75, 95 % CI = 0.65-0.86), but the association was not found in Caucasians. The findings suggest that NF-κB1-94ins/delATTG promoter polymorphism is significantly associated with decreased susceptibility to cancer in overall and Asian population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25190017     DOI: 10.1007/s13277-014-2470-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  40 in total

1.  Statistical aspects of the analysis of data from retrospective studies of disease.

Authors:  N MANTEL; W HAENSZEL
Journal:  J Natl Cancer Inst       Date:  1959-04       Impact factor: 13.506

2.  Multiple nuclear factors interact with the immunoglobulin enhancer sequences.

Authors:  R Sen; D Baltimore
Journal:  Cell       Date:  1986-08-29       Impact factor: 41.582

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

4.  NFKB1 insertion/deletion promoter polymorphism increases the risk of advanced ovarian cancer in a Chinese population.

Authors:  Yaxin Fan; Weijian Yu; Ping Ye; Huali Wang; Zhongmin Wang; Qingli Meng; Ying Duan; Xiaohua Liang; Wanxin An
Journal:  DNA Cell Biol       Date:  2010-12-07       Impact factor: 3.311

Review 5.  The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance.

Authors:  M W Mayo; A S Baldwin
Journal:  Biochim Biophys Acta       Date:  2000-03-27

6.  Genetic analyses of NFKB1 and OCA-B function: defects in B cells, serum IgM level, and antibody responses in Nfkb1-/-Oca-b-/- mice.

Authors:  U Kim; C S Gunther; R G Roeder
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

7.  Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients.

Authors:  Huajie Bu; Inger Rosdahl; Xiao-Feng Sun; Hong Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-11       Impact factor: 4.553

8.  Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis.

Authors:  Amir S Karban; Toshihiko Okazaki; Carolien I M Panhuysen; Thomas Gallegos; James J Potter; Joan E Bailey-Wilson; Mark S Silverberg; Richard H Duerr; Judy H Cho; Peter K Gregersen; Yuqiong Wu; Jean-Paul Achkar; Themistocles Dassopoulos; Esteban Mezey; Theodore M Bayless; Franklin J Nouvet; Steven R Brant
Journal:  Hum Mol Genet       Date:  2003-11-12       Impact factor: 6.150

Review 9.  Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology.

Authors:  Sören Beinke; Steven C Ley
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

10.  Investigation of NF-κB1 and NF-κBIA gene polymorphism in non-small cell lung cancer.

Authors:  Y M Oltulu; E Coskunpinar; G Ozkan; E Aynaci; P Yildiz; T Isbir; I Yaylim
Journal:  Biomed Res Int       Date:  2014-02-23       Impact factor: 3.411

View more
  3 in total

Review 1.  An updated meta-analysis of 37 case-control studies on the association between NFKB1 -94ins/del ATTG promoter polymorphism and cancer susceptibility.

Authors:  Yi-Qiao Luo; Duan Wang; Teng Gong; Jiang Zhu
Journal:  Oncotarget       Date:  2016-09-06

Review 2.  NFKB1 -94insertion/deletion ATTG polymorphism and cancer risk: Evidence from 50 case-control studies.

Authors:  Wen Fu; Zhen-Jian Zhuo; Yung-Chang Chen; Jinhong Zhu; Zhang Zhao; Wei Jia; Jin-Hua Hu; Kai Fu; Shi-Bo Zhu; Jing He; Guo-Chang Liu
Journal:  Oncotarget       Date:  2017-02-07

3.  Genetic association between NFKB1 -94 ins/del ATTG Promoter Polymorphism and cancer risk: a meta-analysis of 42 case-control studies.

Authors:  Duan Wang; Tianhang Xie; Jin Xu; Haoyang Wang; Weinan Zeng; Shuquan Rao; Kai Zhou; Fuxing Pei; Zongke Zhou
Journal:  Sci Rep       Date:  2016-07-22       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.